Levellor ™  Phase [ADDRESS_947349] April 2021 – First Draft                                      
Page  1 of 64  
 
 
 
 
A Physician-Initiated Multiple-Dose, Single  Period, 
Phase 0-I Dose Ranging Study to Examine 
Levellor™  HypoS pray Human Insulin Ad ult 
Healthy Volunteer Patients  
 
  
Protocol No.: LEV 101-D-022521 
ClinicalTrials.gov Reference [STUDY_ID_REMOVED]  
 
 
 
21st APRIL, 2021 
 
Version 1.3 
 
 
 
SPONS OR: Langford Research I nstitute  
  
Principal Investigator : [INVESTIGATOR_236502] D. Kirsh, D.O., M.P.H.  
 
 Approved by [CONTACT_697919] 21
st, 2021  
   
 
  
 
  
 
  
AMENDMENT S: 
 
1.  
2.  
3.  
4. 
 
 
The information in this document contains trade secrets and comme rcial information that are privileged or 
confid ential and may not be disclosed unless such disclosure is required by [CONTACT_774] . In 
any event, persons to whom the information is disclosed must be informed that the information is privileged or 
confid ential and may not be further disclosed by [CONTACT_476]. These restrictions on disclosure will apply  equally  to all 
future information supplied  to you, which is indicated as privileged or confidential. Copyright 2020 Transdermal 
Delivery Solutions Corp dba HypoSpray Pharma.  
  
Levellor ™  Phase [ADDRESS_947350] April 2021 – First Draft                                      
Page  [ADDRESS_947351] of abbreviations .................................................................................................................................. 6 
1.0 Synopsis .............................................................................................................................................. 8 
2.0 Flow Chart .................................................................................................................................... 13 
3.0     Background Information ................................................................ Error! Bookmark not defined.  
3.[ADDRESS_947352]  .................. Error! Bookmark not defined.  
3.2      Introdu ction ................................................................................. Error! Bookmark not defined.  
3.3      Known potential  risks ................................................................ Error! Bookmark not defined.  
3.4      GCP compliance ........................................................................ Error! Bookmark not defined.  
3.5      Populat ion ................................................................................... Error! Bookmark not defined.  
4.0     Trial objectives and purpose  ......................................................... Error! Bookmark not defined.  
4.1      Prima ry objective ....................................................................... Error! Bookmark not defined.  
4.2      Second ary objectives ................................................................ Error! Bookmark not defined.  
5.0     Trial Design ..................................................................................... Error! Bookmark not defined.  
5.1      Overall study design .................................................................. Error! Bookmark not defined.  
5.1.1  Screeni ng .................................................................................. Error! Bookmark not defined.  
5.1.2  Pharm acokinetic Sampling & Response monitoring:  Visit 2 .......... Error! Bookmark not 
defined.  
5.1.3  Pharm acokinetic Sampling& Response monitoring:  Visit 3 (Day 2)  .... Error! Bookmark 
not defined.  
5.1.4  Pharmacokinetic Sampling& Response monitoring:  Visit 4 (Day 3)  .... Error! Bookmark 
not defined.  
5.1.5  Discharge Visit  5: ................................................................ Error! Bookmark not defined.  
5.2      Endpoint s ........................................................................................ Error! Book mark not defined.  
5.2.1   Prima ry Pharmacokinetic  endpoint s ................................... Error! Bookmark not defined.  
Levellor ™  Phase [ADDRESS_947353] April 2021 – First Draft                                      
Page  3 of 64  5.2.2  Second ary endpoi nts .............................................................. Error! Bookmark not defined.  
5.3      Discu ssion of desi gn .................................................................  Error! Bookmark not defined.  
5.4      Visit schedul e and asse ssmen ts ............................................. Error! Bookmark not defined.  
5.4.1  Visit 1 – Pre-Screening Day ................................................... Error! Bookmark not defined.  
5.4.2  Visit 2 – Baseli ne Screen, first dose - Day 1 ........................ Error! Bookmark not defined.  
5.4.3  Visit 3 – Day 2 .......................................................................... Error! Bookmark not defined.  
5.4.4  Visit 4 – Day 3 .......................................................................... Error! Bookmark not defined.  
5.4.5  Visit 5 – Day 4+ ........................................................................ Error! Bookmark  not defined.  
5.5 Random ization  ............................................................................ Error! Bookmark not defined.  
5.5.1  Random ization  .................................................................... Error! Bookmark not defined.  
5.5.[ADDRESS_947354]  identif ication ............................................................... Error! Bookmark not defined.  
5.6      Investigationa l therapy .............................................................. Error! Bookmark not defined.  
5.6.1  Packa ging and labeling ........................................................... Error! Bookmark not defined.  
5.7      Data  collection ............................................................................ Error! Bookmark not defined.  
6.0 Selection and Withdrawal of Subjects ......................................... Error! Bookmark not defined.  
6.1 Inclusi on criteria .......................................................................... Error! Bookmark not defined.  
6.2 Exclusi on criteria ......................................................................... Error! Bookmark not  defined.  
6.3      Screeni ng failure ........................................................................ Error! Bookmark not defined.  
6.4      Withdra wals ................................................................................ Error! Bookmark not defined.  
6.5      Repla cement  of subjects  .......................................................... Error! Bookmark not defined.  
7.0     Treatmen t of Subjects P.R.N.  ..................................................... Error! Bookmark not defined.  
7.1      Treat ments .................................................................................. Error! Bookmark not defined.  
7.2      Concom itant therapy .................................................................  Error! Bookmark not defined.  
7.3      Treat ment complia nce .............................................................. Error! Bookmark not defined.  
8.0     Pharmacokinetic and Therapeutic Paramet ers .......................... Error! Bookmark not defined.  
8.[ADDRESS_947355] ing Time ....................................... Error! Bookmark not def ined.  
Levellor ™  Phase [ADDRESS_947356] April 2021 – First Draft                                      
Page  4 of 64  8.2      Prima ry pharmacokinetic  variables ......................................... Error! Bookmark not defined.  
9.0     Safety and tolerability assessme nts ............................................ Error! Bookmark not defined.  
9.1      Skin evaluation at Human Insulin Levellor™ HypoSpray applicat ion site .. Error! Bookmark 
not defined.  
9.2      Vital signs .................................................................................... Error! Bookmark not defined.  
9.3      Physical examina tion ................................................................ Error! Bookmark not defined.  
9.4.1  Hema tology .............................................................................. Error! Bookmark not defined.  
9.4.2  Blood chemis try ....................................................................... Error! Bookmark not defined.  
9.5      Adverse events .......................................................................... Error! Bookmark not defined.  
9.5.1  Definitions  ................................................................................. Error! Bookmark not defined . 
9.5.2  All adverse events (AEs) ........................................................ Error! Bookmark not defined.  
9.5.3  Serious  adverse events  (SAEs) ............................................. Error! Bookmark not defined.  
9.5.4 Reporti ng procedures .............................................................. Error! Bookmark not defined.  
10.0   Statistics ........................................................................................... Error! Bookmark not defined.  
10.1    Statisti cal methods  .................................................................... Error! Bookmark not defined.  
10.2    Sample size and power calculations  ....................................... Error! Bookmark not defined.  
10.3    Level of significanc e .................................................................. Error! Bookmark not defined.  
10.4    Procedu re for missing, unus ed or spurious data  ................... Error! Bookmark not defined.  
10.5    Selecti on of subjec ts to be include d in the analysis ............. Error! Bookmark not defined.  
10.5.2         Safety Popul ation .......................................................... Error! Bookmark not defined.  
10.5.3    Statisti cal Analysis Methods  ................................................. Error! Bookmark not defined.  
10.6         Safety Data  ....................................................................... Error! Bookmark not defined.  
11.0   Administration ................................................................................. Error! Bookmark not defined.  
11.1    Protocol  amendments ............................................................... Error! Bookmark not defined.  
11.[ADDRESS_947357]  .............................................. Error! Bookmark not defined.  
11.3    End of study ................................................................................ Error! Bookmark not defined.  
Levellor ™  Phase [ADDRESS_947358] April 2021 – First Draft                                      
Page  5 of 64  11.4    Prema ture discont inuation  ........................................................ Error! Bookmark not defined.  
11.5    Monitoring procedures .............................................................. Error! Bookmark not defined.  
12.0   Ethics ................................................................................................ Error! Bookmark not defined.  
12.1    Ethics  and Good Clinical Practice ........................................... Error! Bookmark not defined.  
12.2    Regulat ory and Ethics Committee appro vals......................... Error! Bookmark not defined.  
12.4    Decla ration of Hels inki .............................................................. Error! Bookmark not defined.  
13.0   Data Handling ................................................................................. Error! Bookmark not defined.  
13.1    Data  collectio n ............................................................................ Error! Bookmark not defined.  
13.2    Data  manage ment  and quality control .................................... Error! Bookmark not defined.  
13.[ADDRESS_947359] ing of data and reten tion of doc uments  ....................... Error! Bookmark not defined.  
13.4    Auditing  procedures .................................................................. Error! Bookmark not defined.  
13.5    Handling of study medicat ion ................................................... Error! Book mark not defined.  
14.0   Indem nity and compensation ........................................................ Error! Bookmark not defined.  
15.0  Publica tion Policy ............................................................................ Error! Bookmark not defined.  
15.1  Publica tion of results .................................................................. Error! Bookmark not defined.  
16.0 Appendices ...................................................................................... Error! Bookmark not defined.  
Appendix 1        Declaration of Helsinki 1996 ........................................ Error! Bookmark not defined.  
Appendix [ADDRESS_947360] Information Sheet and Informed Consent .......... Error! Bookmark not defined.  
Appendix 3 Normal Rang es and Clinically Significant Abnormal Vital Signs Error! Bookmark not 
defined.  
Appendix 4        Skin Reaction Scoring Scale ....................................... Error! Bookmark not defined.  
Appendix 5  Blood Sampling for Serum Glucose and  Hum an In sulin  .......... Error! Bookmark  not 
defined.  
Appendix 6        Haematology and Biochem istry sample collection ... Error! Bookmark not defined.  
Appendix 7       Protocol Amendments .................................................... Error! Bookmark not defined.  
 
Levellor ™  Phase [ADDRESS_947361] April 2021 – First Draft                                      
Page  6 of 64   
Levellor ™  Phase [ADDRESS_947362] April 2021 – First Draft                                      
Page  [ADDRESS_947363] aspartate aminotransferase 
 
AUC area under the curve 
 
BP blood pressure bpm
 beats  per minute 
BUN blood urea nitrogen 
Cmax maximal plasma concentration 
 
CPK creatinine phosphokinase 
CNS  central nervous sy stem 
CRF case report form 
EPI [INVESTIGATOR_697909](Adrenalin)  
EU European Union 
 
GCP  Good Clinical Practice 
 
GP General Practitioner 
 
HIV human immunodeficiency virus  
HPS HypoSpray ® pro prietary transdermal delivery system (TDS)   
ICH International Con ference on Harmon ization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
 
IUCD Intrauterine Contraceptive Device 
 
LDH lactate dehydrogenase  
 
LFT Liver Functi on Test 
 
MHRA Medicines and Healthcare products R egulatory Agency 
mm Hg  millimeters of mercury 
NCR  no carbon required 
 
NRS  numerical rating scale 
 
OECD Organisation for Economic Co -operation and Development 
 
PI [INVESTIGATOR_697910] ™  Phase [ADDRESS_947364] April 2021 – First Draft                                      
Page  8 of 64   
 
PK Pharmacokinetics 
RBC red blood cells 
 
REC Research ethics committ ee 
SAP Statistical analysis plan 
SAE Serious adverse event 
SGOT serum glutamic oxaloace tic transaminase (same as AST) 
SGPT serum glutamic pyruvic transa minase (same as ALT) 
S[LOCATION_003]R serious unexpected suspect ed adverse reaction 
T1/2 plasma concentration half life 
TDS® Proprietary transd ermal drug delivery system 
 
Tmax time  pass ed  since  administration  at  which  the  maximum  plasma 
conce ntration occurs 
 
WBC white blood cells (leuko cytes) 
WHO World Health Organization 
Levellor ™  Phase [ADDRESS_947365] April 2021 – First Draft                                      
Page  9 of 64   
1.0 Synopsis 
Name [CONTACT_697938] t/active 
substance  
 
Levellor™  HypoSpray Human Insulin 100 IU/mL  
 
Title of the 
Study A Multi -Dose, Cross -over, Phase 0 Dose Ranging Study to 
Compare Levellor  HypoSpray Human insulin i n Healthy 
Volunteers . 
Protocol 
Numb er/Clinic al 
Phase  
Protocol N o.: LEV 0 01-D-020521   
Phase 0 -1  
Chief 
Investigator  
William Kirsh, D.O.,  M.P.H.   
 
Study Site Clinical Studies Unit  
 
 
 
 
 
 
 
Rationale A new formulation of Human Insulin (Levellor™  HypoSpray ) utilizes the 
HDS HypoSpray® drug delivery system (HypoSpray Pharma, Fl orida, 
[LOCATION_003]) which is  a novel, proprietary transder mal technology, developed  
for use in  pharmaceutic al, cosmetic and over-the-counter products. 
 
Transdermal administration combines a rapid onset of action with a 
conv enient and patient-friendly , and in this case needle- less method of 
administration, which, it is believed, will provide enhanced safety  as a 
more rapid  and long lasting physiological -response alternative to the 
traditio nal SC Injectable route for the administration of Insul in. 
 
This study will assess the volunteer  response  to increasing dose s of 
Human Insulin Levellor  HypoSpray at various doses p.r.n.  compared 
against SC injection  at various sites of application and under v aried 
conditions . 
 
 
 
 
Objectives The primary objective is to determine the amount of lowering serum 
glucose and dose  response to a topi[INVESTIGATOR_697911]  (Levellor™  HypoSpray ) administered by [CONTACT_697920] .  A 2-week 
period of  daily blood sugar monitoring and insulin dosing  for [ADDRESS_947366].  
 
The secondary objective is to evaluate the tolerability and local 
and systemic effects of Levellor™  HypoSpray . 
Design: This is a non-randomized, open label single period, phase 0I study. 
Levellor ™  Phase [ADDRESS_947367] April 2021 – First Draft                                      
Page  10 of  64  Duration o f 
treatment: 
 
  
The maximum study duration is 20 days. 
 
Study 
Popul ation:  
Adult  Male patient volunteers aged [ADDRESS_947368] has a body mass index (BMI) within 18-50 kg/m2. 
 
6. The subject is in otherwis e good health as determined by 
[CONTACT_44059]. 
 
7. The subject is a non-smoker. 
 
8. The subject must agree to continue with dail y serum gluc ose 
testing by [CONTACT_3553] a wearable blood glucose for the 
pharmacokinetic assessments. 
 
9. The subject is willing and able to comply with all testing and 
requirements defined in the protocol. 
 
10. The subject is willing and able to return to the study site for all 
visits.  
Levellor ™  Phase [ADDRESS_947369] April 2021 – First Draft                                      
Page  11 of  64   
 
 
 
 
 
 
 
 
 
 
 
Main Cri teria for 
Exclusion: 1. The subject has any relevant deviations from normal other 
than blood glucose  in physical examination, electrocardiogram 
(ECG), or clinical laboratory tests, as evaluated by [CONTACT_1275]. 
 
2. The subject has had a clinically significant illness within [ADDRESS_947370] a significant volume of blood 
(>450 mL) within four (4) weeks of the study, and their 
Haemoglobin concentration and hematocrit have not returned 
to within 5% of nor mal. 
 
7. The subject has a history of  substance a buse or a current  
positive  urine drug screen or urine alcohol test. 
 
8. Alcohol c onsumption greater than community norms (i.e. more 
than [ADDRESS_947371] drinks per week for males). 
 
9.  Sub jects who have received an investigational drug or have    
used an investigational device in the 30 days prior to study 
entry 
Concomitant 
Medication 
Restrictions  The intake of any medications (OTC or prescription) will be 
vigorously  discouraged except as required to maintain health. 
Total expected 
numbe r of 
subjects Sufficient volunteers will be recruited so as to obtain 5 completed 
subjects.  Up to two additional  subjects may be added.  
Levellor ™  Phase [ADDRESS_947372] April 2021 – First Draft                                      
Page  [ADDRESS_947373] is Human Insulin  (Levellor  
HypoSpray  L). Three  dose ranges will be assessed: administered 
via sprays from a  syringe.  D oses will be calculated from what  the 
literature reports is the low end of He althy V olunte er Insulin 
Sensit ivity. The 3 doses will be 0.075 IU/KG body weight, 0.1 
IU/KG B ody weight and 0.15 IU/KG Body Weight .  This will result 
in dose ranges of  5 to 20 I Us. 
Levellor ™  Phase [ADDRESS_947374] April 2021 – First Draft                                      
Page  13 of  64   
 
Randomi zation Subjects will not be randomized.  S ites of application: applied 
topi[INVESTIGATOR_697912]/chest arm , thigh area or inner aspect of a 
forearm . 
 
 
Dosage  Patients will receive  dosing from the investigato r and docu ment 
blood sugar  with a weara ble C ontinuous Glucose Monitor (Libr e 2) 
and will be dosed  for [ADDRESS_947375] dose and longer if available up to 7  days  before 
beginning the study routine and 3 days af ter and receive  the study 
drug via topi[INVESTIGATOR_697913] .  
 
Th d  ill b Ij td  I M   ll  d d  lid 
           
        
 
 
 
 
 
 
Criteria for 
evaluation:  Pharmacokinetics 
 
Prima ry pharmacokinetic variables 
 
The primary pharmacokinetic variables include: the reduc tion of 
serum glucose from baseline and at typi[INVESTIGATOR_697914] r eduction.  
 
In addition to 90% confidence intervals, the data will be 
summarized by [CONTACT_7864], and maximum and minimum values. 
 
The elimination half-life of Insulin will be compared using non-
transformed data and parametric techniques.  Averages for the 
serum glucose and Post prandial excursions  will be compared 
against aver ages for experimental periods.  
 
 
  
 
 
 
 
 
 
 
 
Safety and 
Tolerabil ity 
  
Adverse Events will be recorded throughout the study, at all visits 
and during any telephone calls. 
 
Details on medical history and conc omitant illnesse s will be 
recorded on the day of screening by [CONTACT_168486] a medical 
interview of subject or subject relative(s) and/or review of the 
subject’s medical records. Any ch anges observed or reported 
during the study will be recorded. 
 
A brief physical examination will be performed at Screening and 
at the Final Visit. 
 
 
Clinical laboratory tests will be performed at Screening, and on the 
days of Human Insulin  administration, serum glucose levels will be 
monitored by m eans of a wearable C ontinuous Glucose Monitor.  
 
Levellor ™  Phase 0 Protocol HVD1   Healt hy Volunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                          
Page  [ADDRESS_947376] Dose  Visit 5 
Discharge  
Informed consent X     
Inclusion/exclusion criteria X X X X X 
Demography X     
Medical history X     
Brief physical examination X     
Vital signs X X  X X 
Concomitant medication X X  X  
Local skin evaluation: clinical  
 X X  X  
Hematology, biochemistry and 
urinalysis X X  X  
Serum Glucose  Profile Test* X X X X X 
Urine Drug Screen X     
Randomization X     
Topi[INVESTIGATOR_697915]   X X X  
Patient Questionnaires     X 
Adverse events  X X X X 
 
* Normal pre an d post meal and pre - and post bedtime T ime Points as measured by [CONTACT_697921] ™  Phase 0 P rotocol HVD1  Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021 – First Draft      
Page  1 of 64 
A Physician-Initiated, Multiple-Do se, Single  Perio d, 
Phase 0-I Do se Rangi ng Study to Examine 
Levellor™  HypoS pray Human Insulin Ad ult 
Healthy Volunteer Patients  
VOLUNTEER DOCLOSURES  
Protoc ol No.: LEV 101-D-0 [ZIP_CODE] 
ClinicalTrials.gov R eference [STUDY_ID_REMOVED] 
21st APRIL, 2021 
Versi on 1.3 
SPONSOR: Langford Research I nstitute  
Pr
incipal Investigator: W illiam D. Kirsh, D.O., M.P.H.  
A
pproved by [CONTACT_697919] 21st, 2021  
AMENDMENT S: 
1. 2. 3. 4. 
The informa tion in this docu ment contains t rade secrets and co mme rcial informa tion that are pr ivileged or 
confiden tial and may not be dis closed unless su ch disclosure is required by [CONTACT_697922]. I n 
any event, persons to whom the informa tion is disclos ed must be infor med that the informa tion is privileged or 
confiden tial and may not be furth er disclosed by [CONTACT_476]. These restr ictions on dis closure w ill apply  equally  to all 
future informa tion su pplied  to you, wh ich is indicated as pr ivileged or confidenti al. Copyright 2020 Transdermal 
Delivery Solutions Corp dba HypoSpray Pharma.  
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  [ADDRESS_947377] Information Sheet and Informed Consent 
 
(Form to be  on headed pape r) 
 
Study Number: LEV 101-D-[ADDRESS_947378] Identification Number:  
 
Study title: 
  
A Physician -Initiated  , Mul tiple-Dose, Single Period, Phase 0- I Dose  Ranging 
Study to Examine Levellor™ HypoSpray Human Insulin Adult Healthy Volunteer 
Patients  
 
 
IND No:       NA Phase 0 
Spons or:       Langford Research I nstitute 
Version number: 1.0 
 
Part 1 
Invitation 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it will 
involve.  Please  take time to read the following information carefully.  Talk to 
others about the study if you wish. 
 
 Part 1 tells you the purpose of this study and what will happe n to you if 
you take part. 
 Part [ADDRESS_947379] Institute is the sponsor of this research. 
 
What is the purpos e of the study? 
The purpose of the study is  to measure the extent of the absorption (through the 
skin and into the blood) of several doses of Human Insul in from a new 
formulation of this well-know n medicine.  It is belie ved that the new transd ermal 
route i.e. through the skin, will provide a rapid onse t of action, and be more 
convenient and use r-friendly than the traditio nal injection  route for the 
administration of Human Insulin . This study will examine your blood glucose 
response  profiles to Human Insulin  applie d via the skin with a new delivery 
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  [ADDRESS_947380] I been approached? 
You are being asked to take part in this study becaus e you are an adult aged 
between [ADDRESS_947381] to take part? 
No. It is up to you to decide whether or not to take part.  If you do, you will be 
given this information sheet  to keep and be asked to sign a conse nt form. You are 
still free to withdraw at any ti me and without giving a reason.  A decisi on to 
withdraw at any time, or a decisio n not to take part, will not affect the standard of 
care you receive. 
 
What will happen  to me  if I take part? 
If you agree to take part, you will be required to attend the clinic on four (4) 
occasions to see the doctor/nurse. Two (2) of these  visits will last only an hour 
each . The total study period for most will be a maximum of 35 days including the 
screening visit.  A minimum of 7 volunteers will be recruited to the study. 
 
The requirements of the study and your participation are descr ibed as follows: 
 
At every visit we will check your general health and perform a brief physical 
examination, including blood pressure and pulse rate. 
 
Screening Visit 
(This will occur no more than [ADDRESS_947382] administration of study 
medication) 
 
If you agree to take part and to sign a “Consent for Study Screening” you will be 
invited  to  a  selection  session  with  the  Endocrine  Investigations  Unit . 
 
You will be examined by [CONTACT_39635], who will take a detailed medical history 
and conduct a brief physical examination, including blood pressure and pulse  rate 
and we will ask you about  your medication and ask about any drug and/or alcohol 
abus e. We will ask you to provide a urine sample to test for drugs of abus e. 
 
Before joining the study we will require a 30mL blood sample from your arm for 
routine safety tests (about six (6) tablespoons.  
 
With your permission we will contact [CONTACT_697923]. 
 
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  4 of 64  
Visit 2 – Baseline 
Once accepted into the study, we will ask you to come to the Clinical Trial s Unit in 
the early morning.  At this time you will undergo a check-in procedu re and sign a 
“Consent for Study Participation”. 
 
We will start by [CONTACT_697924] c ontinuous glucose moni tor CGM (a small 
button with a small si ze needl e) into your arm if you haven’ t already  done so, by 
[CONTACT_515388] g the instructions on the pa ckage .  By [CONTACT_697925] a needle  each 
time. After the last sample  day, the CGM button  can be removed.  
 
The Human Insulin  dose will be sprayed topi[INVESTIGATOR_697916],  or 
your forearm or thigh an d you will be asked to rub it in gently. At [ADDRESS_947383] of this; you will not be identifiable from the 
photograph. 
 
We will also measure your heart rate and blood pressure. 
 
During the day you can stay within the Unit but  are not required t o. It is most 
important that you are relaxed and are not stressed or excited as this may alter 
your own natural Human Insulin  production and confuse the study results.  You 
should pl an to eat lunch at the same time each of  the 3 dosing days  and you 
should try to eat roughly the same thing each day.  
 
 
In between dosing visits 
We will call you by [CONTACT_697926] 2 and 3 to confirm 
your continued participation, daily dose  sched ule and eligibility (including 
conco mitant medication use) as well as the occurrence  of adverse events.  
 
Visit 5 (Final dose) - Day 6+ 
We will ask you to come to the Clinical Trials  Unit in the early morning.  At this 
time you will underg o a check- in procedure. 
 
We will start by [CONTACT_697927].  The blood samples on this day  are 
to calculate whether  you are returning to your normal pattern of glucose rising 
before to just after and falling after meals  has resumed. We will also measure your 
heart rate and blood pressure at regular intervals.  After th e last polling, the CGM 
can be removed.  
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  [ADDRESS_947384] to do ? 
If you choose to take part in this study you must not be taking part in other study. 
You must also not have taken part in any other study within the last [ADDRESS_947385] inform your research doctor. 
 
 
 
What is the drug,  device or procedure  that is being tested? 
The HypoSpray Pharma  System (HypoSpray®) is a combination of harmless 
chemicals at very low dose s, which are balanced to deliver drugs through the skin 
without a needle, pain or irritation. These chemicals are usually used in 
cosmetics foods and food supplements. The HDS® system release s the dr ug 
where it is intended to have its effect without changing the drug in any way. 
 
Human Insulin is the horm one that the body creates to sti mulate the conversion of 
fat to sugars the bod y needs for ener gy.  Th e ho rmone is critical in helpi[INVESTIGATOR_697917] .    
 
What are the alternatives for diagnos is or treatment? 
There are no al ternative treatments to  Human Insulin except the injectable form.  
In the unlikely e vent of a reacti on, you will be t reated with the appropriate remedy 
which might be a dose of glucose or other sugar by [CONTACT_697928] a 
sugary foodstuff or d rink like a soft  drink .  The medicines being used in the study 
are believed to be the easiest and least invasive to use. 
 
 
 
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  6 of 64 What are the side effects of any treatment received when taking part? 
Most Common: Application site reaction, abnorm al lab test results.  The severity 
of these side effects usually  depends on the size of the dose of Human Insulin  
and may continue throughout the study. 
 
Less common: Headache, dizziness,  hypoglycemia and problems passi ng water. 
 
Very Rare: Heart attack or stroke.   We do not  expect this, but it is possible.  
 
What are the other possible  disadvantages and risks of taking part? 
The chemicals used in all of the HypoSpray® system are mainly used in the 
cosmetics and foods industries and are known to be safe for skin application. 
Additionally, we will  be using them at very low concentrations compared to other 
products. We have recently finished two studies using HypoSpray ® with local 
anest hetics in 100 volunteers HypoSpray ® with Testosterone  in a further 17 
volunteers and  HypoSpr ay ® with Diazepam  in [ADDRESS_947386] while the skin is still wet after dosing, 
with anyone who is or might be pregnant while you are participating in this trial.  
 
What are the possible benefits of taking part? 
This study may not benefit you directly; however it may lead to the development 
of a more effective transder mal (delivery through the ski n) version of Human 
Insulin . 
 
What happens when the research study stops? 
You will be free to go home. 
 
What if there is a problem? 
Any complaint about the way you have been dealt  with during the study or any 
possi ble harm you might suffer will be addressed.  The detailed information on 
this is g iven in part 2. 
 
If you have a complaint, please contact [CONTACT_697929]:  [CONTACT_697941] m Kirsh . 
 
If you feel any discomfort or distress during the investigations, you must say so 
and we will stop the tests immediately at any time. 
 
If you are employed by [CONTACT_697930],  non-participation or dropp ing out of the 
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  [ADDRESS_947387] number for complaints will be given. 
 
Will my taking pa rt in t he study be kept confidential? 
Yes. All the information about your participation in this study will be kept 
confidential. The details are included in Part 2. 
 
Contact D etails: 
If you require any further information, please 
contact:  
 
[CONTACT_697931]: [CONTACT_697942]: [PHONE_14506] 
 
 Or: 
 
After -hours number: [PHONE_14506]  
 
This completes Part 1 of the Information Sheet. 
 
If the information in Part 1 has interested you and you are consi dering 
participati on, please continue to read the additio nal information in Part 2 before 
making any decisi on. 
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  8 of 64  
Part 2 
 
What if relevant new information becom es available? 
Sometimes, during the course of a research project, new in formation beco mes 
available  abou t the treatment/drug that is being studied.  If this happens,  your 
research doctor will tell you about it and discuss whether you want to or should 
conti nue in the study.   If you decide not to carry on, your research doctor will 
make arrangements for your care to continue. If you decide to continue in the 
study, you will be asked to sign an updated conse nt form. 
 
Also, on receiving new information your research doctor might consider it to be in 
your best interests to withdraw you from the study.  He/she will explain the 
reasons and arrange for your c are to continue. 
 
If the study is stopped for any other reason, you will be told why, and your 
conti nuing care will be arrang ed. 
 
What will happen if I don’t  want to carry on with the study? 
If you withdraw from the study, we will need  to use the data collected up to your 
withdrawal. We would ask you to keep  in contact [CONTACT_697932].  Information collected may still be used.  Any stored blood or tissue 
samples that can still be identified, as yours will be destroyed if you wish. 
 
If your participati on in the study is  discontinued after you have started taking the 
study drug you will be asked to undergo a final examination for your own safety. If 
the reason for ending the study is, for example, an adverse event or a side-effect 
of the drug, you will be asked to give information on these in order to protect the 
other patients taking part in this clin ical study. 
 
What if there is a problem? 
If you are harmed by [CONTACT_697933], ther e are no special 
compensation arrangements. If you are harmed due to someone’s negligence, 
then you may have grounds for a legal action, but you may have to pay for it. 
Regardless of this, if you wish to complain, or have any conc erns about any 
aspect of the way you have been approached or treated during the course of this 
study, the normal National Health Service complaints mechanisms should be 
available  to you. 
 
Compl aints: 
If you have a concern about any aspect of this study, you should ask to speak 
with the Research Doctor who will do their best to answ er your questi ons ([CONTACT_697943] , telephone: [PHONE_14506] ).  If you remain unhappy and wish to 
complain formally you can do this by [CONTACT_13172]: 
The Complaints Officer: c/o Chief Operating Officer for the Clinical Unit Center . 
 
Confidential  
Levellor ™  Phase 0 Protocol HVD1   Healthy V olunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                                      
Page  9 of 64 Will my taking pa rt in t his study be kept confidential? 
All the information obtained about you in the course of the study is confidential 
according to rules an d will be kept in a secure locked room. The investigators 
performing the study an d a study Monitor will have access to the data collected in 
this study.  They may a lso be looke d at by [CONTACT_697934]. All will have a duty of confidentiality to you as a 
research participan t and nothing that could reveal your identity  will be disclosed 
outside the research site. 
 
Involvement of t he General Practitioner/Family doctor (GP) 
With your permission we will contact [CONTACT_697923]. 
 
What will happen to any sampl es I give? 
All your blood and urine samples taken for safety screening and for drugs of 
abuse will be tested immediately in the clinical lab  and once the results are 
obtained, they will be destroyed.  
 
Will any genetic tests be done?  
 
No genetic tests will be done for this study. 
 
What will happen to the results of the research study? 
The results of this study may be published or presented at meetings.  You will not 
be identified in any report / publication or presentation. 
 
Who is  organizing and funding the research? 
This research is being spons ored by [CONTACT_697935].  
 
Who has reviewed the study? 
This study has been given a favorable ethical opi[INVESTIGATOR_697918] d Research Institute.    
 
Before you sign this consent form, please ask any questi ons you have about 
the study.  Thank you for taking the time to read this information sheet. 
 
Level lor ™  Phase 0 Protocol HVD1   Healt hy Volunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                          
Page  10 of  64 Study Numb er: LEV 101-D-[ADDRESS_947388] Identification N umber: _______  
SCREENING  CONSE NT FORM  
 
Title of Project: 
 
A  Multiple-Dose, Single Period, Phase 0 -I Dose  Ranging Study t o Examine 
HDS®-Human Insulin in Adult Subject s 
 
Name [CONTACT_236160]: [CONTACT_697944] initial box 
 
1.  I confirm that I have read and understand the information sheet 
dated ............................ , (version .......................) for the above study. I 
have had t he opportunity to consider the information, ask questi ons and 
have had these  answ ered satisfactorily.  
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected.  
3. I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by [CONTACT_697936], where it is relevant to 
my taking part in this research.  I give permission for these individuals to  
have access to  my records and understand that my records will be 
maintained confi denti al.  
4.  I agree to my GP being informed of my participation in the study if 
necessary .  
5. I agree to take part in the above study.  
 
  
Name [CONTACT_697939] ™  Phase 0 Protocol HVD1   Healt hy Volunteer Dose Rang e Trial ver 1.0 25th February  2021  – First Draft                          
Page  11 of  64  
Study Numb er: LEV 101-D-[ADDRESS_947389] Identification N umber: ______  
 
STUDY CONSE NT FORM  
 
A  Multiple-Dose, Single Period, Phase [ADDRESS_947390] s 
 
Name [CONTACT_236160]: [CONTACT_697945] iam Kirsh  
Please initial box 
 
1.  I confirm that I have read and understand the information sheet 
dated ............................ , (version .......................) for the above study. I 
have had the opportunity to consider the information, ask questions and 
have had these  answ ered satisfactorily.  
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected.  
3. I understand that relevant sections of any of my medical notes and data 
collected during the study, may be looked at by [CONTACT_697937], where it is relevant 
to my taking part in this research.  I give permission for these individuals to  
have access to  my records.  
4.  I agree to my GP being informed of my participation in the study.  
5. I agree to take part in the above study.  
 
  
Name [CONTACT_697940] 
 